研究人员在利什曼病寄生虫中发现了一种新的酶,这可能导致更好的治疗。 Researchers found a new enzyme in leishmaniasis parasites that could lead to better treatments.

堪萨斯大学的研究人员发现了寄生虫的新途径,导致人类利什曼病,这一疾病每年影响约100万人。 Researchers at the University of Kansas have discovered a new pathway in parasites that cause human leishmaniasis, a disease affecting about 1 million people annually. 这一突破确定了CYP5122A1酶,这对寄生虫的乙醇生产至关重要。 This breakthrough identifies the CYP5122A1 enzyme, which is crucial for the parasite's ergosterol production. 以前,Azole antfungal药物是无效的,但以这种新途径为目标可导致更有效地治疗利什曼病。 Previously, azole antifungal drugs were ineffective, but targeting this new pathway could lead to more effective treatments for leishmaniasis.